64.3 Longitudinal Tobacco Cessation Pharmacotherapy

Epidemiology, Health Burden & Timeline of Cessation Benefits

Tobacco use remains the single leading preventable cause of premature death, disability, and disease in the United States, accounting for over 480,000 deaths each year (approximately 1 in every 5 deaths). Smoking drives catastrophic morbidity across three major clinical domains: cardiovascular disease (atherosclerosis, myocardial infarction, stroke, peripheral artery disease), chronic pulmonary disease (COPD, emphysema, refractory asthma exacerbations), and oncologic malignancies (causing $>85%$ of all lung cancers, as well as cancers of the larynx, bladder, kidney, pancreas, esophagus, and cervix).

The Clinical Timeline of Health Recovery After Cessation

Cessation delivers profound, measurable physiological benefits across immediate and long-term timeframes:

• 20 Minutes: Heart rate and blood pressure decline toward baseline.
• 12 Hours: Blood carbon monoxide levels drop to normal, restoring arterial oxygen-carrying capacity.
• 2 Weeks to 3 Months: Circulation improves, lung function ($FEV_1$) increases by up to 10%, and acute myocardial infarction risk begins to fall.
• 1 to 9 Months: Coughing and shortness of breath decrease; bronchial ciliary function recovers, dramatically clearing pulmonary secretions and reducing respiratory infection risk.
• 1 Year: Excess risk of coronary heart disease drops by 50% compared to that of a continuing smoker.
• 5 Years: Stroke risk drops to that of a non-smoker (5 to 15 years post-cessation).
• 10 Years: Lung cancer mortality rate is approximately half that of a continuing smoker; risk of mouth, throat, esophagus, bladder, cervix, and pancreas cancer declines substantially.
• 15 Years: Risk of coronary heart disease equals that of a lifetime non-smoker.

---

Brief Clinical Behavioral Counseling: The 5 A's & The 5 R's

The USPSTF assigns a Grade A recommendation to screening all adults for tobacco use, advising all tobacco users to quit, and providing behavioral interventions and FDA-approved pharmacotherapy to all non-pregnant adults who smoke.

                      THE 5 A'S FRAMEWORK FOR PATIENTS READY TO QUIT

   Step        Clinical Action                         Practical Clinical Application & Phrasing
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   1. ASK      Screen at every encounter               "Do you currently use any form of tobacco, cigarettes,
                                                       or electronic vaping devices?"
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   2. ADVISE   Clear, strong, personalized advice      "Quitting smoking is the single most important step you can
               to quit delivered with empathy          take to protect your heart and help manage your COPD."
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   3. ASSESS   Determine willingness to make a quit    "Are you willing to make a quit attempt within the next
               attempt in the next 30 days             30 days?"
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   4. ASSIST   Provide behavioral counseling plus      • Set a firm QUIT DATE (within 2 to 4 weeks).
               first-line pharmacotherapy              • Prescribe Varenicline or Combination NRT.
                                                       • Identify personal triggers and social supports.
                                                       • Connect to state quitlines (1-800-QUIT-NOW).
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   5. ARRANGE  Schedule structured follow-up           Schedule in-person or telephone follow-up contact within
               contact to ensure accountability        1 to 2 WEEKS after the quit date to monitor adherence,
                                                       manage drug side effects, and prevent relapse.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

The 5 R's Framework for Patients Unwilling to Quit

For patients ambivalent or not currently ready to make a quit attempt within the next 30 days, clinicians should deploy Motivational Interviewing (MI) using the 5 R's framework to build internal motivation:

1. Relevance: Encourage the patient to identify why quitting is personally relevant (e.g., their children's asthma, personal finances, athletic performance).
2. Risks: Ask the patient to identify acute risks (shortness of breath, exacerbations), chronic risks (heart disease, cancer), and environmental risks (secondhand smoke harm to household members).
3. Rewards: Prompt the patient to identify tangible benefits of quitting (food tasting better, saving thousands of dollars annually, improved stamina, home/car smelling clean).
4. Roadblocks: Help the patient identify barriers to quitting (fear of withdrawal, weight gain, stress, living with another smoker) and brainstorm practical mitigation strategies.
5. Repetition: Re-evaluate readiness and repeat the motivational intervention at every subsequent clinical encounter without badgering or alienating the patient.

---

Evidence-Based First-Line Pharmacotherapies

Unassisted "cold turkey" quit attempts carry a dismal long-term success rate of only 3% to 5% at 6 to 12 months. Combining structured behavioral counseling with first-line pharmacotherapy increases 6-month abstinence rates to 25% to 35%. Three first-line pharmacotherapeutic classes are approved by the FDA:

                  COMPARATIVE SUMMARY OF FIRST-LINE CESSATION PHARMACOTHERAPIES

   Therapy             Mechanism of Action             Dosing & Administration          Key Clinical Pearls & Risks
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Varenicline         α4β2 nicotinic acetylcholine    • Days 1–3: 0.5 mg daily         MOST EFFECTIVE SINGLE AGENT;
   (Chantix)           receptor (nAChR) partial        • Days 4–7: 0.5 mg BID           superior to Bupropion & single NRT;
                       agonist; provides dual action   • Day 8–Wk 12: 1 mg BID          take with full glass of water & food;
                       (agonist + antagonist)          (continue to 24 wks if needed)   EAGLES trial: SAFE in psychiatric disease.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Combination NRT     Long-acting patch (steady       • Patch: 21 mg/day (if ≥ 10 cig) EQUIVALENT EFFICACY TO VARENICLINE;
   (Patch + PRN Gum /  basal level) PLUS short-acting  or 14 mg/day (if < 10 cig)       vastly superior to single-agent NRT;
   Lozenge / Inhaler)  agent (PRN breakthrough bolus)  • Gum/Lozenge: 4 mg (if 1st cig  "Chew and park" technique for gum;
                                                       ≤ 30 min) or 2 mg (> 30 min) PRN avoid acidic drinks 15 min prior.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Bupropion SR        Norepinephrine-dopamine         • Days 1–3: 150 mg daily         Non-nicotine oral tablet;
   (Zyban /            reuptake inhibitor (NDRI);      • Day 4–Wk 12: 150 mg BID        PREVENTS POST-CESSATION WEIGHT GAIN;
   Wellbutrin SR)      weak nAChR antagonist           (taken ≥ 8 hours apart)          CONTRAINDICATED IN SEIZURES, BULIMIA,
                                                                                        ANOREXIA NERVOSA; safe in CAD.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Varenicline (Chantix)

• Mechanism of Action: Varenicline is a synthetic small molecule that acts as a selective partial agonist at $\alpha_4\beta_2$ neuronal nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area (VTA):
  • Partial Agonism: It produces approximately 30% to 60% of the maximal dopamine release stimulated by nicotine. This basal dopamine release satisfies the mesolimbic reward center, mitigating intense cravings and suppressing acute withdrawal symptoms.
  • Competitive Antagonism: Because varenicline binds the $\alpha_4\beta_2$ receptor with higher affinity than nicotine, if the patient lapses and smokes a combustible cigarette, varenicline competitively prevents inhaled nicotine from binding the receptor. This blocks the surges of dopamine, blunting the reward, satisfaction, and positive reinforcement of smoking.
• Efficacy: Multiple network meta-analyses and Cochrane reviews demonstrate that varenicline is the most effective single agent for tobacco cessation, achieving superior 6-month continuous abstinence rates compared to bupropion monotherapy (Odds Ratio [OR] $\approx 1.6$) and single-agent NRT monotherapy (OR $\approx 1.7$).
• Dosing & Titration Protocol:
  • Start medication 1 to 2 weeks prior to the target quit date (allows drug levels to reach steady state before cessation):
    • Days 1 to 3: 0.5 mg orally once daily in the morning.
    • Days 4 to 7: 0.5 mg orally twice daily (morning and evening).
    • Day 8 through Week 12: 1.0 mg orally twice daily.
  • Maintenance: If the patient achieves complete abstinence at 12 weeks, continue varenicline for an additional 12 weeks (total 24-week course) to consolidate abstinence and prevent late relapse.
• Adverse Effects & Administration Pearls:
  • Nausea: The most frequent side effect (occurring in up to 30% of patients). It is generally mild-to-moderate and diminishes over time. Clinical Pearl: Instruct patients to take varenicline immediately after a meal with a full 8-ounce glass of water to significantly reduce nausea.
  • Neuropsychiatric & Sleep Symptoms: Vivid, abnormal, or bizarre dreams and insomnia are common. Administering the second daily dose at dinner rather than right before bedtime helps mitigate sleep disturbances.
• The EAGLES Landmark Trial & Removal of Black Box Warning:
  • In 2009, post-marketing reports prompted the FDA to mandate a black box warning regarding potential neuropsychiatric events (depression, suicidal ideation, agitation).
  • The landmark EAGLES trial (Evaluating Adverse Events in a Global Smoking Cessation Study; $>8,000$ participants, including $>4,000$ with clinically stable psychiatric disorders) definitively demonstrated no significant difference in neuropsychiatric adverse events between varenicline, bupropion, transdermal nicotine patch, and placebo. In 2016, the FDA removed the black box warning. Varenicline is safe and effective in smokers with stable depression, anxiety, or schizophrenia.

2. Combination Nicotine Replacement Therapy (Combination NRT)

• The Flaw of NRT Monotherapy: Single-agent NRT (such as using a nicotine patch alone or nicotine gum alone) has modest efficacy (OR $\approx 1.6-1.8$ vs. placebo) because:
  • A transdermal patch delivers slow, steady, 24-hour background nicotine levels but cannot provide rapid bolus spikes to extinguish sudden, intense situational cravings.
  • Short-acting oral agents (gum, lozenges) provide acute bolus relief but fail to maintain steady basal nicotine levels, leading to frequent subacute withdrawal dips throughout the day.
• The Combination Regimen: Combining a long-acting transdermal patch (providing steady 24-hour basal nicotine levels) with a short-acting PRN formulation (gum, lozenge, oral inhaler, or nasal spray for acute breakthrough cravings) achieves clinical efficacy equivalent to varenicline and is vastly superior to single-agent NRT.
• Transdermal Nicotine Patch Dosing:
  • If patient smokes $\ge 10$ cigarettes/day (half a pack or more):
    • Step 1: 21 mg/24 hours transdermal patch for 4 to 6 weeks.
    • Step 2: 14 mg/24 hours patch for 2 weeks.
    • Step 3: 7 mg/24 hours patch for 2 weeks.
  • If patient smokes $< 10$ cigarettes/day:
    • Start at Step 2: 14 mg/24 hours patch for 6 weeks.
    • Step 3: 7 mg/24 hours patch for 2 weeks.
  • Application Pearls: Apply to clean, dry, non-hairy skin on the upper trunk or outer arm daily upon waking. Rotate sites daily to prevent contact dermatitis. If patient experiences vivid dreams or nocturnal insomnia, instruct them to remove the patch at bedtime (16-hour daily wear).
• Short-Acting Breakthrough Formulations:
  • Nicotine Gum & Lozenge:
    • Dosing is based on the "Time to First Cigarette" (TTFC) upon waking (the best single measure of biological nicotine dependence):
      • First cigarette $\le 30\text{ minutes}$ after waking: Use the 4 mg strength.
      • First cigarette $> 30\text{ minutes}$ after waking: Use the 2 mg strength.
    • Dosing Schedule: 1 piece every 1 to 2 hours PRN for cravings (minimum 9 pieces/day for the first 6 weeks; maximum 20 to 24 pieces/day).
  • The "Chew and Park" Technique for Nicotine Gum:
    • Patients must be explicitly counseled that nicotine gum is NOT chewed like regular confectionery bubblegum.
    • Instructions: Chew the gum slowly until a peppery taste or slight tingling sensation is felt in the mouth. Immediately "park" the gum between the cheek and buccal gum mucosa. When the tingling subsides (after ~1 minute), chew again until tingling returns, then park in a different location. Repeat over 30 minutes, then discard.
    • Rationale: Chewing continuously causes the patient to swallow nicotine with saliva, which causes severe dyspepsia, throat burning, hiccups, and nausea, while stomach acid and hepatic first-pass metabolism inactivate over 80% of the swallowed drug. Nicotine must be absorbed trans-mucosally through the oral buccal mucosa.
  • Avoid Acidic Beverages:
    • Acidic beverages (coffee, sodas, citrus juices, wine, beer) dramatically lower salivary pH, converting nicotine into its ionized, charged form, which cannot permeate the lipid-rich buccal mucosa.
    • Clinical Rule: Avoid drinking or eating anything (except plain water) for at least 15 minutes before and during the use of nicotine gum or lozenges.
  • Nicotine Oral Inhaler: Delivers 4 mg of nicotine vapor into the oral cavity (buccal absorption) via a mouthpiece. Highly satisfying for smokers who miss the behavioral "hand-to-mouth" ritual.
  • Nicotine Nasal Spray: Rapidly delivers nicotine across the nasal mucosa, achieving the fastest peak serum levels of any NRT (reaches brain within 5–10 minutes). Causes initial nasal burning, sneezing, and lacrimation; high compliance barrier.

3. Bupropion Sustained-Release (Zyban, Wellbutrin SR)

• Mechanism of Action: Bupropion is a monocyclic aminoketone that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and non-competitive antagonist at neuronal nicotinic receptors. By inhibiting the reuptake of dopamine and norepinephrine in the mesolimbic system and locus coeruleus, bupropion mimics the neurochemical actions of nicotine, blunting withdrawal symptoms and reducing craving.
• Key Clinical Niche: Bupropion is particularly advantageous for smokers who express intense concern about post-cessation weight gain. It significantly attenuates weight gain during active therapy (though weight gain often catches up once the drug is discontinued). It is also an ideal dual-purpose agent for patients with comorbid mild-to-moderate major depressive disorder.
• Dosing Protocol:
  • Start medication 1 to 2 weeks before the target quit date:
    • Days 1 to 3: 150 mg orally once daily in the morning.
    • Day 4 through Week 12: 150 mg orally twice daily.
    • Administration Rule: Doses must be taken at least 8 hours apart, and the second dose should be taken in the late afternoon (before 5 PM) to minimize insomnia.
• STRICT CONTRAINDICATIONS & SAFETY WARNINGS:
  1. History of Seizure Disorder: Bupropion lowers the epileptic seizure threshold in a dose-dependent manner (seizure incidence is $\approx 0.1%$ at doses $\le 300\text{ mg/day}$).
  2. Current or Prior Diagnosis of Anorexia Nervosa or Bulimia Nervosa: Patients with eating disorders taking bupropion exhibit a substantially elevated incidence of generalized tonic-clonic seizures due to electrolyte shifts and intrinsic susceptibility.
  3. Abrupt Discontinuation of Alcohol, Benzodiazepines, or Other Sedatives: Further lowers the seizure threshold.
  4. Concurrent Use of Monoamine Oxidase Inhibitors (MAOIs): Requires a mandatory 14-day washout period.
• Cardiovascular Safety: Unlike nicotine, bupropion does not elevate blood pressure or heart rate significantly and is entirely safe in patients with stable coronary artery disease and heart failure.

---

Special Clinical Populations & E-Cigarettes

1. Pregnant Smokers

Smoking during pregnancy causes severe maternal and fetal morbidity: spontaneous abortion, intrauterine growth restriction (IUGR), low birth weight ($<2500\text{ g}$), placenta previa, placental abruption, premature rupture of membranes, preterm birth, and Sudden Infant Death Syndrome (SIDS).

• First-Line Intervention: Intensive behavioral counseling is the first-line and preferred intervention throughout pregnancy.
• Pharmacotherapy Decisions: If behavioral counseling fails and the patient continues to smoke heavily, clinicians may engage in shared decision-making regarding NRT.
  • Intermittent short-acting formulations (nicotine gum or lozenges) are preferred over 24-hour continuous patches to minimize overall fetal nicotine exposure.
  • If a patch is required, instruct the patient to remove it at bedtime (16-hour wear).
  • Varenicline and bupropion are generally avoided as initial agents due to limited human safety data in pregnancy.

2. Electronic Cigarettes (E-Cigarettes / Vaping)

• USPSTF Recommendation: The USPSTF concludes that the current evidence is INSUFFICIENT to assess the balance of benefits and harms of electronic nicotine delivery systems (ENDS / e-cigarettes) for tobacco cessation in adults.
• Clinical Hazards & The "Dual-Use" Pitfall:
  • Aerosols from e-cigarettes contain nicotine, ultrafine toxic particles, volatile organic compounds (formaldehyde, acrolein), diacetyl (associated with bronchiolitis obliterans / "popcorn lung"), and heavy metals (nickel, tin, lead).
  • EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury): Outbreak characterized by acute respiratory failure, bilateral pulmonary infiltrates, and severe hypoxemia, strongly linked to vitamin E acetate used as a thickening agent in unregulated or illicit vaping cartridges.
  • The Dual-Use Trap: Many adults who attempt to quit smoking by vaping become "dual users"—smoking combustible cigarettes while also vaping. Dual users experience no reduction in cardiovascular morbidity or mortality and maintain high nicotine dependence.
  • Youth Addiction Crisis: E-cigarettes have fueled a nationwide epidemic of nicotine addiction among adolescents and young adults, acting as a gateway to combustible tobacco use.
• Clinical Recommendation: Primary care clinicians should advise patients against using e-cigarettes for smoking cessation and instead prescribe FDA-approved first-line therapies (varenicline or combination NRT) supported by behavioral counseling.